Robert Yoder - Trevena Senior Vice President and Chief Business Officer
| TRVNDelisted Stock | USD 1.98 0.18 10.00% |
President
Mr. Robert T. Yoder is Senior Vice President and Chief Business Officer of the company. Mr. Yoder joined Trevena as Vice President of Commercial Operations and Sales in June 2018. Prior to this, he served as Senior Vice President and Head of Global Commercial Operations, Alliance Management and IT at Orexigen Therapeutics, Inc., a biopharmaceutical company, from March 2015 through June 2018. While at Orexigen, Mr. Yoder built the commercial infrastructure with a focus on innovative, efficient, and effective business process and architecture. Additionally, he led external business development efforts that delivered 11 partnership deals spanning 67 countries. Prior to joining Orexigen, Mr. Yoder spent 28 years at Merck Co., where he held various roles of increasing responsibility across global business operations and commercial functions. In several of these roles, he was responsible for oversight and execution of largescale initiatives including integration following acquisitions and led a range of organizational design and corporate change initiatives since 2018.
| Age | 58 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 610 354 8840 |
| Web | https://www.trevena.com |
Robert Yoder Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Yoder against Trevena stock is an integral part of due diligence when investing in Trevena. Robert Yoder insider activity provides valuable insight into whether Trevena is net buyers or sellers over its current business cycle. Note, Trevena insiders must abide by specific rules, including filing SEC forms every time they buy or sell Trevena'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Yoder over two months ago Disposition of 443 shares by Robert Yoder of Trevena at 1.55 subject to Rule 16b-3 | ||
Robert Yoder over a year ago Payment of 36688 shares by Robert Yoder of Trevena subject to Rule 16b-3 |
Trevena Management Efficiency
The company has return on total asset (ROA) of (0.7151) % which means that it has lost $0.7151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1458) %, meaning that it created substantial loss on money invested by shareholders. Trevena's management efficiency ratios could be used to measure how well Trevena manages its routine affairs as well as how well it operates its assets and liabilities.Trevena currently holds 35.23 M in liabilities with Debt to Equity (D/E) ratio of 0.56, which is about average as compared to similar companies. Trevena has a current ratio of 5.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Trevena's use of debt, we should always consider it together with its cash and equity.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. Trevena operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people. Trevena (TRVN) is traded on NASDAQ Exchange in USA. It is located in 955 Chesterbrook Boulevard, Chesterbrook, PA, United States, 19087 and employs 23 people. Trevena is listed under Pharmaceutical Products category by Fama And French industry classification. Management Performance
| Return On Equity | -10.15 | ||||
| Return On Asset | -0.72 |
Trevena Leadership Team
Elected by the shareholders, the Trevena's board of directors comprises two types of representatives: Trevena inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Trevena. The board's role is to monitor Trevena's management team and ensure that shareholders' interests are well served. Trevena's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Trevena's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Demitrack, Senior Vice President and Chief Medical Officer | ||
| Michael Catalano, Vice Marketing | ||
| Howard MD, Consultant Founder | ||
| Robert Yoder, Senior Vice President and Chief Business Officer | ||
| Mark MD, Senior Officer | ||
| Carrie Bourdow, Senior Vice President Chief Commercial Officer | ||
| Patricia Drake, Senior Officer | ||
| Barry Shin, Senior CFO | ||
| Joel Solomon, General VP |
Trevena Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Trevena a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.15 | ||||
| Return On Asset | -0.72 | ||||
| Operating Margin | (20.01) % | ||||
| Current Valuation | 21.78 M | ||||
| Shares Outstanding | 852.93 K | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 8.77 % | ||||
| Number Of Shares Shorted | 59.36 K | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 0.36 X |
Pair Trading with Trevena
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Trevena position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Trevena will appreciate offsetting losses from the drop in the long position's value.Moving together with Trevena Stock
Moving against Trevena Stock
| 0.74 | VCYT | Veracyte | PairCorr |
| 0.56 | VERA | Vera Therapeutics | PairCorr |
| 0.55 | DMAC | DiaMedica Therapeutics Trending | PairCorr |
| 0.51 | VAXX | Vaxxinity | PairCorr |
| 0.47 | DRTS | Alpha Tau Medical | PairCorr |
The ability to find closely correlated positions to Trevena could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Trevena when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Trevena - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Trevena to buy it.
The correlation of Trevena is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Trevena moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Trevena moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Trevena can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Trevena Stock
If you are still planning to invest in Trevena check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Trevena's history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |